Possible "costs" and "savings" to the provinces of Bill C-22. : RG47-19/1986E-PDF
"Bill C-22 provides for a transitional phase-in of the periods of market exclusivity. Because provincial governments have been expecting a number of generic drugs to be on the market sooner than the Bill provides for, there will be transitional adjustment assistance to the provincial governments of $100 million over 4 years. This note derives the possible "cost" estimate based on a "worst case scenario" basis. In addition, it reports the possible savings to consumers due to the presence of the Drug Prices Review Board"--Introduction.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.883873&sl=1
| Ministère/Organisme | Canada. Consumer and Corporate Affairs Canada, issuing body. |
|---|---|
| Titre | Possible "costs" and "savings" to the provinces of Bill C-22. |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Format | Électronique |
| Document électronique | |
| Note(s) | Digitized edition from print [produced by Innovation, Science and Economic Development Canada]. |
| Information sur la publication | [Ottawa] : Consumer and Corporate Affairs Canada, Bureau of Policy Coordination = Consommation et corporations Canada, Bureau de la coordination des politiques, [1986] |
| Description | 1 online resource (5 pages) |
| Numéro de catalogue |
|
| Descripteurs | Canada. Patent Act. Drugs -- Prices -- Canada. Patent licenses -- Canada. Médicaments -- Prix -- Canada. Licences de brevets -- Canada. |